Welcome to our dedicated page for Elevance Health news (Ticker: ELV), a resource for investors and traders seeking the latest updates and insights on Elevance Health stock.
Elevance Health, Inc. operates a health benefits and healthcare services platform built around affiliated health plans and the Carelon services business. Recurring company news covers Health Benefits results, premium yields, medical-cost trends, Medicaid, Medicare Advantage and employer group membership, and Carelon activity in pharmacy services, behavioral health, value-based care, care delivery, clinical, home health and complex care solutions.
Company updates also address small and midsize employer benefit offerings such as Balanced Funding and MEWAs, primary-care recognition and value-based provider programs, partnerships tied to family and community health, annual and quarterly financial guidance, and leadership changes across Health Benefits and Carelon.
Elevance Health (NYSE: ELV) reported its Q2 2024 results, with operating revenue of $43.2 billion and adjusted operating gain of $2.8 billion. The company's diluted EPS increased by 26% to $9.85, while adjusted diluted EPS rose 12% to $10.12. Elevance Health declared a Q3 2024 dividend of $1.63 per share.
The benefit expense ratio improved to 86.3%, while the operating expense ratio increased to 11.7%. The company maintains its full-year outlook, expecting GAAP net income per diluted share to be at least $34.05 and adjusted diluted net income per share to be at least $37.20 in 2024.
Elevance Health's Health Benefits segment saw a 2% decrease in operating revenue, while Carelon segment's operating revenue increased by 10% compared to the prior year quarter.
Elevance Health has released its annual Impact Report, showcasing its transformation from a traditional health insurance company to a comprehensive healthcare services provider. Key achievements include receiving the Health Equity Accreditation Plus from the National Committee for Quality Assurance, supporting Medicaid eligibility renewals, and expanding Carelon. The company was recognized among America’s top 50 most community-minded companies and featured in JUST Capital’s JUST 100. The report emphasizes Elevance Health’s efforts to cater to the unique needs of each health plan member, assess and address health drivers, form community partnerships, and utilize data-driven insights to enhance and personalize healthcare services.
Elevance Health (NYSE: ELV) will announce its second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. EDT. A conference call to discuss these results and the company's outlook will follow at 8:30 a.m. EDT. The domestic access number for the call is 888-947-9963 with the access code 3972058, and for international participants, the number is 312-470-0178 with the same access code. A replay of the call will be available domestically at 800-391-9851 and internationally at 203-369-3268 from 11:30 a.m. EDT on July 17 until August 17, 2024. Additionally, the call will be accessible via a live webcast on the Elevance Health website under the 'Investors' section.
Elevance Health (NYSE: ELV) will present at Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida on June 12 at 1:20 p.m. EDT. Senior management will deliver the presentation, which will be webcast live on the company's investor relations website. A replay of the presentation will be available for 90 days following the event. Interested individuals are advised to visit the website early to download any necessary software. This presentation will reflect Elevance Health's recent SEC filings, including their Annual Report on Form 10-K for the year ending December 31, 2023.
Elevance Health (NYSE: ELV) announced its participation in Bernstein's 40th Annual Strategic Decisions Conference in New York City on May 31 at 9:00 a.m. EDT.
Senior management will present critical company updates. Interested parties can access a live webcast through Elevance Health's investor site.
A replay will be available for 90 days post-presentation.
Listeners are advised to review Elevance Health's recent SEC filings, including the 2023 Annual Report on Form 10-K.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.